ERA

Download the full-sized PDF of The Role of RUNX3 in Chemoresistance in Epithelial Ovarian CancerDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3K931F2K

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

The Role of RUNX3 in Chemoresistance in Epithelial Ovarian Cancer Open Access

Descriptions

Other title
Subject/Keyword
Ovary
Cancer
RUNX3
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Zepeda, Nubia I
Supervisor and department
YangXin, Fu (Oncology)
Examining committee member and department
Weinfeld, Michael (Oncology)
Hitt, Mary (Oncology)
Steed, Helen (Obstetrics and Gynecology)
Murray, David (Oncology)
Department
Department of Oncology
Specialization
Experimental Oncology
Date accepted
2014-06-05T14:48:59Z
Graduation date
2014-11
Degree
Master of Science
Degree level
Master's
Abstract
Chemoresistance is one of the major hurdles to induce a cure in patients with epithelial ovarian cancer (EOC). RUNX3, belonging to the family of RUNX transcription factors, has been shown to act in an oncogenic manner by promoting proliferation and colony formation when overexpressed, in EOC. However, to date the role of RUNX3 in chemoresistance in EOC has not been studied. Based on its oncogenic role in EOC, we want to determine whether RUNX3 contributes to chemoresistance in EOC. In our study we found that RUNX3 expression is elevated in human EOC samples when compared to non-cancerous ovarian cells. RUNX3 expression is variable in EOC cell lines. Interestingly A2780s cells, a cisplatin-sensitive ovarian adenocarcinoma cell line, show little expression of RUNX3 at the protein level. A2780cp cells, which were derived from A2780s cells by exposure to step-wise increasing doses of cisplatin, show high expression of RUNX3. In A2780s and A2780cp cells, treatment with carboplatin increases the expression of RUNX3 at the protein level. When RUNX3 is overexpressed in EOC cells, cells become slightly more resistant to carboplatin treatment. When we knock down the expression of RUNX3 in A2780cp cells, no effect on cell sensitivity to carboplatin is observed. However, dominant-negative (dn) expression of RUNX3 in A2780cp cells made cells more sensitive to the effects of carboplatin. The dn form may be binding to and occupying the sites that RUNX family members recognize, or binding to the common co-factor CBFβ. Based on these results, we conclude that RUNX3 plays a minor role in chemoresistance when overexpressed in EOC and that other factors, such as other RUNX family members, may be compensating for the loss of RUNX3 when it is knocked down. In the future, it would be interesting to block all the RUNX family members, and observe whether chemoresistant cells become more sensitive to carboplatin treatment. Next we took a systematic approach to understanding chemoresistance by examining the paired human EOC cell lines, A2780s and its derivative A2780cp, using a microarray analysis. To identify networks and pathways that may be key during acquired chemoresistance we conducted an extensive literature search and put the data into Ingenuity Pathway Analysis (IPA) software. Our microarray and IPA suggest that Wnt signaling may be upregulated in A2780cp cells, although further experiments are needed to confirm this. In the future we plan to modulate the canonical Wnt pathway in A2780cp and A2780s cells, and determine whether activation of the canonical Wnt pathway is playing a role in chemoresistance in EOC.
Language
English
DOI
doi:10.7939/R3K931F2K
Rights
This thesis is made available by the University of Alberta Libraries with permission of the copyright owner solely for the purpose of private, scholarly or scientific research. This thesis, or any portion thereof, may not otherwise be copied or reproduced without the written consent of the copyright owner, except to the extent permitted by Canadian copyright law.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-06-05T20:49:10.694+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (PDF/A)
Mime type: application/pdf
File size: 2670004
Last modified: 2016:11:16 13:48:49-07:00
Filename: Zepeda_Nubia_I_201406_MSc.pdf
Original checksum: 78ffe6c69c614c3421631ac181358819
Activity of users you follow
User Activity Date